Scientists from a collaboration of Australian research institutions have proposed that editing multiple genetic variants in ...

Intellia Therapeutics (NTLA) stock falls, sending its gene editing rivals lower, as Wall Street reacts to its latest layoff ...

Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment, which uses ...

While some mutations in the BRCA2 gene clearly indicate risks for breast and prostate cancer, thousands of less-common ...

If corn was ever jealous of soybean's relationship with nitrogen-fixing bacteria, advancements in gene editing could one day even the playing field. A recent study shows that gene-edited bacteria can ...

Rice plants can deal with the heat during the day, but when the sun goes down, they need to chill out. Developing rice with ...

Colossal, values the Dallas-based startup at a staggering $10.2 billion. Besides making it the first startup founded in Texas ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Yoltech Therapeutics Co. Ltd. has advanced YOLT-204 into the clinic for the treatment of transfusion-dependent β-thalassemia (TDT). If successful, YOLT-204 may provide an off-the-shelf curative ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought ...